Cancer Research 09 AM Call for Abstracts  SU2C
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 67, 4364-4372, May 1, 2007. doi: 10.1158/0008-5472.CAN-06-1898
© 2007 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Casimiro, M.
Right arrow Articles by Albanese, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Casimiro, M.
Right arrow Articles by Albanese, C.

Experimental Therapeutics, Molecular Targets, and Chemical Biology

ErbB-2 Induces the Cyclin D1 Gene in Prostate Epithelial Cells In vitro and In vivo

Mathew Casimiro1, Olga Rodriguez2, Llana Pootrakul3, Maral Aventian2, Nadia Lushina2, Caroline Cromelin2, Georgina Ferzli2, Kevin Johnson2, Stanley Fricke2, Fantahun Diba2, Bhaskar Kallakury2, Chioma Ohanyerenwa2, Maxine Chen4, Michael Ostrowski5, Mien-Chie Hung6, Shafaat A. Rabbani7, Ram Datar3, Richard Cote3, Richard Pestell1 and Chris Albanese2

1 Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania; 2 Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, District of Columbia; 3 Keck School of Medicine, University of Southern California, Los Angeles, California; 4 Rutgers University, New Brunswick, New Jersey; 5 Ohio State University, Columbus, Ohio; 6 M. D. Anderson Cancer Center, University of Texas, Houston, Texas; and 7 McGill University Health Center, Montreal, Canada

Requests for reprints: Chris Albanese, Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057. Phone: 202-687-3305; E-mail: albanese{at}georgetown.edu.

The receptor tyrosine kinase ErbB-2 plays an important role in the regulation of growth factor–induced signal transduction cascades in the epithelium, and ErbB-2 is frequently overexpressed in epithelial tumors. Our previous studies on clinical prostate cancer specimens indicated that ErbB-2 expression was increased in patients undergoing hormone ablation therapy. We had also shown that the critical cell cycle regulatory gene cyclin D1 and its promoter were targets of proliferative signaling in prostate cancer cell lines, and that cyclin D1 was required for ErbB-2–induced mammary tumorigenesis. In the current studies, we found that increased ErbB-2 membrane expression correlated with increased nuclear cyclin D1 staining in clinical prostate cancer specimens, and that expression of ErbB-2 was capable of inducing cell cycle progression in human prostate cancer cell lines. We further showed that ErbB-2 induced the cyclin D1 promoter in DU145 cells, and that small interfering RNA knockdown of cyclin D1 protein levels blocked a significant proportion of the heregulin-induced cell cycle progression in LNCaP cells. Probasin promoter–targeted expression of an activated ErbB-2 isoform induced cyclin D1 expression in the mouse prostate, commensurate with prostate intraepithelial neoplasia. Together, these in vitro and in vivo studies identify cyclin D1 as a critical downstream target of ErbB-2 in the prostate epithelium, both of which are possible therapeutic targets for cancer intervention. Furthermore, our novel mouse model provides a useful platform for ongoing in vivo investigations of ErbB-2 signaling in the prostate epithelium. [Cancer Res 2007;67(9):4364–72]




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
L. J. Inge, S. A. Rajasekaran, D. Wolle, S. P. Barwe, S. Ryazantsev, C. M. Ewing, W. B. Isaacs, and A. K. Rajasekaran
{alpha}-Catenin overrides Src-dependent activation of {beta}-catenin oncogenic signaling
Mol. Cancer Ther., June 1, 2008; 7(6): 1386 - 1397.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2007 by the American Association for Cancer Research.